Abstract: An optical microscope (10) comprising a first optical microscope (R); and a second optical microscope (Q) with a different mode of operation to the first optical microscope (R). The optical microscope (10) is configured such that the first optical microscope (R) and the second optical microscope (Q) simultaneously view a sample on a sample stage (I).

Abstract: Methods for processing and sorting sperm are disclosed. Portions of sperm sorting or staining processes may include standardizing sperm samples by adjusting the concentration of the sperm sample to a predetermined concentration and adjusting the pH of the sample to a predetermined value. Sperm may also be stained in a single staining buffer having a DNA selective dye and a quenching dye.

Abstract: In accord with the present invention, the fertility quality of an ejaculate can be determined by assaying sperm, in aliquots of the ejaculate or of an ejaculate produced previously by the same male, at intervals over a period of time. Fertility quality is determined by the number of times the level of expression of a marker on the sperm goes through a maximum level of expression during the period of time and if desired by sperm state and fertilization procedure used. The marker should be capable of correlation with the level of Fc receptor (FcR) expression on the sperm. The fertility quality of the ejaculate is related to the number of times a maximum level of expression is reached.

Abstract: Systems, methods, and apparatuses for providing dynamic, prioritized spectrum utilization management. The system includes at least one monitoring sensor, at least one data analysis engine, at least one application, a semantic engine, a programmable rules and policy editor, a tip and cue server, and/or a control panel. The tip and cue server is operable utilize the environmental awareness from the data processed by the at least one data analysis engine in combination with additional information to create actionable data.

Abstract: A system and method are provided for producing from a first fluid having particles of a substance suspended or dissolved therein with a first concentration of the substance, a second fluid having a second concentration of the substance lower than the first concentration and a separated-fluid product, in which concentration of the substance is greater than that in the first fluid. The system comprises a pre-treatment module for processing the first fluid to produce aggregates from the substance and at least one separation duct in fluid communication with an outlet of the pre-treatment module, the duct having at least one bay portion having such design as to cause aggregates to accumulate along a pre-determined wall of the bay portion, thereby facilitating separation between the second fluid and the separated-fluid product.

Abstract: A method for treating spermatozoa of an animal includes: irradiating the spermatozoa with light having wavelengths in a range of 390-420 nm at a fluence effective to increase motility of the spermatozoa by 75% or more.

Abstract: A method of in vitro fertilization wherein the embryo is implanted into the uterus of a female patient at least two, and preferably three to twelve months after the eggs are retrieved from the patient in order to reduce the effect of autoimmune rejection of the embryo by the patient's autoimmune system and increase the probability and success of pregnancy and wherein prior to embryo implantation, the endometrium in the uterus is prepared for embryo implantation by introducing peripheral blood mononuclear cells (PBMCs) into the uterus. The procedure is combined with cryopreservation techniques to preserve the oocytes or the IVF-produced embryos of the patient.

Abstract: An acellular, anion-depleted platelet-derived peptide-rich composition comprising proteins, polypeptides and peptides <10 kDa in size, wherein the composition has anti-microbial and/or anti-inflammatory activity is disclosed. The composition can be substantially free of non-active and immunogenic factors. The composition can have a platelet-to-bacteria ratio ?1000:1. The composition can comprise plasma at a range of ?10% to ?50% plasma, optionally about 10% plasma. Methods of using the composition are also disclosed.

Abstract: The present disclosure discloses an in-vitro method for detecting presence of metabolically altered cells. Also, an in-vitro method for detecting presence of quiescent cells has been disclosed. The present disclosure discloses an in-vitro method for detecting and predicting presence of cancer. The present disclosure discloses an in-vitro method for monitoring response to anti-cancer therapy. The present disclosure analyses expression of at least one biomarker of pluripotent stem cell for detecting or predicting or monitoring cancer. A related use of the at least one biomarker of pluripotent stem cell marker along with a method of treatment comprising the in-vitro method of detection or prediction has been disclosed herewith.

Abstract: An organ-on-a-chip microfluidic device is disclosed that mimics a human lymph node and/or human lymphoid tissue. The device can include cells from human blood and lymphatic tissue, include an extracellular matrix for the development of immune system components, and provide for the perfusion of fluids and solids resembling blood and lymphatic fluid within micrometer sized channels.

Abstract: Extracts obtained from the genus Hippophae or other plant sources or compositions produced by chemical or molecular biological techniques each having in common certain moieties in amounts effective when combined with reproductive cells to reduce the loss of function.

Abstract: Red blood cell products and compositions are disclosed. The product includes a container made from PVC or a non-PVC material that is substantially free of a phthalate plasticizer but otherwise includes one or more non-phthalate plasticizers or extractable agents. The product includes a RBC concentrate which has been combined with an additive solution for storing the RBCs.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Provided are a vitrification stabilizer for an animal cell cryopreservation fluid, and an animal cell cryopreservation fluid which exhibits superior vitrification capabilities due to the animal cell cryopreservation fluid containing the vitrification stabilizer for an animal cell cryopreservation fluid. The vitrification stabilizer for an animal cell cryopreservation fluid contains: an amphoteric polymer compound selected from the group consisting of (a) a carboxylated amphoteric polymer compound obtained by reacting ?-poly-L-lysine with butyl succinic anhydride, (b) a carboxylated amphoteric polymer compound obtained by reacting ?-poly-L-lysine with butyl succinic anhydride and succinic anhydride, or (c) a carboxylated amphoteric polymer compound obtained by reacting ?-poly-L-lysine with a compound represented by formula I; and (d) a sucrose polymer macromolecule to which epichlorohydrin has been crosslinked.

Abstract: Provided herein are RNA agent-loaded platelets, methods of preparing RNA agent-loaded platelets, and methods of using RNA agent-loaded platelets. In some embodiments, methods of loading RNA agents into platelets include treating platelets with a RNA agent, a cationic transfection reagent, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

Abstract: The present disclosure relates to the cosmetology field, in particular to an activated revitalizing lotion and its preparation method and application. A preparation method of an activated revitalizing lotion comprises the steps of: mixing an isolated blood sample, ozone-oxygen mixture and sodium citrate, and centrifuging the mixed blood sample at 1800-2000 r/min for 9-10 min to obtain a plasma supernatant for use as an activated revitalizing lotion; the ozone-oxygen mixture has an ozone concentration of 42.8-171.4 ?g/L and added in an amount of 2.3-3.2 L/1 L of the isolated blood sample; and sodium citrate is added in an amount of 0.2-0.3 mg/1 L of the isolated blood sample. The activated revitalizing lotion prepared by the preparation method of the present disclosure shows improved effect in repair and revitalization of skin or subcutaneous tissues.

Abstract: A blood storage container along with an aqueous composition for the storage of packed red blood cells is described. In a preferred embodiment, the container is not made of DEHP plasticizer. In some embodiments, the container is made from a polymeric material and a non-DEHP plasticizer. In some embodiments, the aqueous composition is made of about 1 to about 3 mM adenine, about 20 to about 115 mM dextrose, about 15 to about 60 unmetabolizable membrane-protectant sugar, about 20 to about 30 mM sodium bicarbonate, and about 4 to about 20 mM disodium phosphate. In a most preferred embodiment, the DEHP-lacking container is made from a PVC polymeric material and a DINCH plasticizer and the aqueous composition is made of about 2 mM adenine, about 80 mM dextrose, 55 mM unmetabolizable membrane-protectant sugar, about 26 mM sodium bicarbonate, and about 12 mM disodium phosphate.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: Provided herein are systems and method for measuring cell stiffness. In particular, provided herein are microelectrode configuration and systems for measuring platelet deformation and stiffness.

Abstract: The present invention generally relates to a process suitable for extracorporeal lung support. The process comprises contacting blood with a dialysis liquid separated by a semipermeable membrane. Oxygen is introduced into blood and/or into the dialysis liquid prior to contacting blood and dialysis liquid being separated by the semipermeable membrane. The process is versatile and allows for blood oxygenation as well as removal of at least one undesired substance occurring in the blood, selected from carbon dioxide, bicarbonate and hydrogen cations, from blood. Thereby, the present invention takes advantage of the Haldane effect in the extracorporeal contacting step. The undesired substance can be efficiently transported across a semipermeable membrane to the dialysis liquid.

Abstract: A diagnostic biological array, kit or system, and method of using same unit for conducting simultaneously blood tests and determining the presence of diseases, the blood type, and blood quality of a blood sample and its applications.

Abstract: Provided are systems and methods for treating a biological fluid, e.g., to inactivate pathogens.

Abstract: A composition for preserving viability of cells, tissues, or organs at a low temperature is provided. The composition includes a mitochondrial uncoupling agent, at least one protease inhibitor, and a reducing agent. Methods to protect cells, tissues, or organs from exposure to cold and other metabolic stress are also provided.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: A system and method are provided for wet storage of tissue. In an embodiment, a solution for the wet preservation of tissue may include between about 0.1% to about 50% by volume dimethyl sulfoxide (DMSO) and one or more soluble monovalent or divalent metal cationic salts. A wet-preserved tissue and method for preparing the wet-preserved tissue for ultimate use, is also provided.

Abstract: Peritoneal dialysis, such as automated peritoneal dialysis (“APD”) is provided with any one or more or all of the following sensing or feedback features: impedance sensing to detect peritonitis, temperature sensing to detect peritonitis, bio-MEMS sensing to detect peritonitis, and glucose control for diabetes patients, wherein each sensing or feedback feature analyzes patient effluent fluid or fluid dwelling within a patient's peritoneal cavity.

Abstract: The present disclosure provides for a cell stabilizing medium which comprises gelatin. The cell stabilizing medium help maintain cell viability, e.g., after thawing of a biological material post-cryopreservation.

Abstract: A method of image-based analysis of multiple samples includes using a sample holder having multiple locations of interest and multiple focal structures that are each associated, one or more, with the multiple locations of interest, wherein the multiple samples are dispersed across the multiple locations of interest and obtaining image areas of the multiple locations of interest. Multiple digital image areas are thus obtained for use in an analysis of the multiple samples with each of the image areas including at least one of the locations of interest and at least one of the focal structures. An image processing algorithm is used to analyse each of the digital image areas and check if the focal structure indicates that the image area is in clear focus. An indication is provided and/or remedial action is taken if the image processing algorithm indicates that any digital image areas are out of focus.

Abstract: A system and methodology for the preservation of red blood cells is described in which red blood cells are oxygen or oxygen and carbon dioxide depleted, treated and are stored in an anaerobic environment to optimize preparation for transfusion. More particularly, a system and method for extended storage of red blood cells from collection to transfusion that optimizes red blood cells prior to transfusion is described.

Abstract: The present invention relates to a system (100) for extracorporeal blood treatment comprising a first inlet (1) for introducing a bloodstream to be treated into the system (100), three blood treatment apparatus (A, D, G), as well as an outlet (2) for discharging a treated bloodstream from the system (100), wherein the system comprises an adsorber apparatus (A) and/or a plasma separator apparatus, a dialysis apparatus (D) and a gas exchange apparatus (G), and wherein the three blood treatment apparatus (A, D, G) are sequentially connected in series in a functional state of system (100) application between the inlet (1) and the outlet (2) of the system relative to a direction of blood flow of a bloodstream to be treated and can be consecutively perfused extracorporeally by a bloodstream to be treated.

Abstract: The invention encompasses a rapid and safe preparation method of sperm nuclei, improved sperm nuclei and a method of using the improved sperm nuclei to calibrate a flow cytometer with higher accuracy.

Abstract: A plasma separation system and process for providing filtered plasma from a blood sample is described. The system may include a blood separation well having a separation membrane for filtering the blood sample. The filtering process may be aided by the use of a negative or positive pressure source attached to the plasma separation system.

Abstract: The invention relates to a device (1) for applying an electric field to a suspension of cells, cell derivatives, organelles, sub-cellular particles and/or vesicles, comprising at least one chamber (6) which comprises at least two electrodes (4), and at least one separating element (13) which is movable within the chamber (6) between two terminal points (14, 15) and, if it is in a position between the terminal points (14, 15), separates at least one first compartment (26) of the chamber (6) from at least one second compartment (27) of the chamber (6).

Abstract: Distributed liquid-flow systems—in which flow spreads out from a system inlet and traverses the system through multiple discrete, smaller flow channels—are constructed to minimize variations in flow-resistance-induced pressure drop from the system inlet to entrances to the flow channels. Because flow-driving pressure will be more uniform at the entrances to the flow channels, flow along the channels will be more uniform. Disclosed embodiments may be particularly suitable or advantageous for use in gas-exchange/artificial lung devices.

Abstract: An immunoassay includes forming first mixtures by reacting a combination reagent with serum of a subject; simultaneously forming second mixtures by reacting randomly selected platelet samples with the serum wherein in each mixture there are immunity compounds formed by combining the platelet antigens with predetermined antibodies in the serum, and other platelet antigens and other antibodies in the serum not forming the immunity compounds; preparing an interception device including receptacles and a filter net; placing each mixture in one receptacle; washing the mixtures wherein the mixtures forming the immunity compounds are intercepted by the filter net with others passing through; adding a signal sensing reagent to each receptacle; reacting the signal sensing reagent with the intercepted mixtures forming the immunity compounds to form final products; and performing a signal sensing to determine whether the final products contain anti-platelet antibodies and determine compatibility of cross matching of resp

Abstract: Disclosed herein are methods and compositions for preserving avulsed teeth and/or explanted tissue. The disclosed methods for preserving avulsed teeth and/or explanted tissue typically include placing the avulsed teeth and/or explanted tissue in a preservation solution comprising at least about 2.75 g/L sugar. Suitable explanted tissues for the disclosed methods may include explanted tissues comprising fibroblasts, such as dental tissue and/or oral tissue. The preservation solution of the disclosed preservation methods may include additional components which may include but are not limited to inorganic salts, amino acids, vitamins, and buffering agents. The preservation solution may be prepared from a powder formulation having a long shelf-life.

Abstract: A pure platelet-rich plasma (P-PRP) composition as an alternative to conventional antibiotic treatment of subclinical mastitis caused by Gram-positive bacteria in bovine including five live platelets and leukocytes, an anticoagulant, and an activating substance.

Abstract: A system for processing fluids and filling a container with a product includes a disposable fluid circuit and reusable hardware configured to accept the disposable fluid circuit. The disposable fluid circuit includes a spinning membrane separator, first and second syringes, and a flow control cassette. The reusable hardware includes a drive coupled to the spinning membrane separator, first and second syringe pumps, the first and second syringes coupled to the first and second syringe pumps respectively, and a controller. The system also includes a syringe pump for filling low-volume containers, which syringe pump may be one of the first and second syringe pumps, or may be a third syringe pump. The syringe pump for filling low-volume containers may include a filtered vacuum/pressure source and a position detector.

Abstract: Provided are a diluent and a sperm preservation method using the diluent. The diluent is useful in preservation of sperm with high fertility, and is capable of stably achieving quality control and improving quality of the sperm. Refrigerating or freezing sperm using the diluent for sperm, which includes an aqueous solution containing at least one oligosaccharide selected from the group consisting of a fructo-oligosaccharide, an isomalto-oligosaccharide, a gentio-oligosaccharide, and a galacto-oligosaccharide, can improve the quality of preserved sperm and provide sperm having high fertility, at a reduced cost.

Abstract: Provided herein is technology relating to cryopreservation and particularly, but not exclusively, to devices, systems, and methods for cryopreservation of biological materials such as oocytes, zygotes, and embryos. In particular, provided herein are methods of using microfluidic devices to exposing biological material to a vitrification solution having a time dependent concentration of a cryoprotectant agent.

Abstract: Method for transfusion medicine to reduce adverse events in transfusion patient populations based on underlying patient physiology. Methods for reducing the risk of an inflammatory response in a sickle cell patient in need of a blood transfusion.

Abstract: The present invention is related to the field of tissue regeneration. It concerns more particularly new standardizations and medical devices for the preparation of A-PRP, PRP, BMC, fat tissue, alone or in combination with a biomaterial or cell extract.

Abstract: A method of forming a semiconductor device includes forming source/drain contact openings extending through at least one dielectric layer to expose source/drain contact regions of source/drain structures. The method further includes forming conductive plugs in the source/drain contact openings. The method further includes depositing a light blocking layer over the conductive plugs and the at least one dielectric layer. The method further includes etching the light blocking layer to expose the conductive plugs. The method further includes directing a laser irradiation to the conductive plugs and the light blocking layer. The laser irradiation is configured to activate dopants in the source/drain contact regions.

Abstract: A method for treating a blood specimen with which capturing rates for both a small rare cell and a rare cell having a high deformability can be improved in the case where rare cells are contained in a blood specimen. The method for isolating or detecting a rare cell includes treating a blood specimen using a filter to isolate or detect a rare cell in the blood specimen.

Abstract: The present invention relates to a method for obtaining an antibody from an avian B cell antibody library, comprising the following steps (a) to (d): (a) a step of allowing an avian B cell antibody library to come into contact with an antigen in the presence of a calcineurin inhibitor and avian serum, (b) a step of selecting avian B cells that bind to the antigen in the step (a), (c) a step of culturing the avian B cells selected in the step (b) in the presence of a calcineurin inhibitor and avian serum, and (d) a step of obtaining the avian B cells obtained through the step (c) and/or an antibody expressed by the avian B cells.

Abstract: The present invention provides a method for determining the gender of a fetus by assaying the sex hormones, evaluating the overall reducing/oxidizing (redox) activity, and/or evaluating the radical scavenging capacity of the maternal urine or other body fluid. The method can be used to determine fetal gender at any time point during pregnancy. The methods of the present invention also provide for a means for pre-conception offspring gender planning by assaying the sex hormones in urine samples, evaluating the overall reducing/oxidizing (redox) activity, and/or evaluating the radical scavenging capacity of the urine or other body fluid from a non-pregnant female. In some embodiments, the methods described herein are used to sort sperm based on an overall reducing/oxidizing environment of follicular fluids, which can then be used for intrauterine insemination.

Abstract: The present invention relates to devices and methods of use thereof for detection of biomolecules, in vitro, in vivo, or in situ. The invention relates to methods of diagnosing and/or treating a subject as having or being at risk of developing a disease or condition that is associated with abnormal levels of one or more biomolecules including, but not limited to, inter alia, epilepsy, diseases of the basal ganglia, athetoid, dystonic diseases, neoplasms, Parkinson's disease, brain injuries, spinal cord injuries, and cancer. The invention also provides methods of differentiating white matter from gray matter. In some embodiments, regions of the brain to be resected or targeted for pharmaceutical therapy are identified using sensors. The invention further provides methods of measuring the neurotoxicity of a material by comparing microvoltammograms of a neural tissue in the presence and absence of the material using the inventive sensors.

Abstract: A method for sterilising a platelet lysate in the liquid state comprising at least the endogenous growth factors TGF-beta 1, EGF, PDGF-AB, IGF-1, VEGF and bFGF. The method comprising freezing the liquid platelet lysate in order to obtain a frozen platelet lysate, and irradiating the frozen platelet lysate with ionising radiation in order to obtain a sterilised platelet lysate, the irradiation being adapted so as to preserve at least 80% of the concentration of at least one of the endogenous growth factors chosen from the group consisting of TGF-beta 1, EGF, PDGF-AB, IGF-1 and VEGF.

Abstract: Provided is a blood component separation device and related method, each capable of separating a blood component from blood and rapidly performing a virus inactivation process on the separated blood component. The blood component separation device includes a blood component separation section, provided in a centrifuge, configured to separate a blood component from blood by centrifugation, a diluting section configured to dilute, in a diluent containing riboflavin, concentrated red blood cells separated by the blood component separation section, and a UV light emitting unit configured to perform a virus inactivation process by exposing the concentrated red blood cells thus diluted to the UV light.

Abstract: The invention described herein relates to a method and kit for the diagnosis of antiphospholipid syndrome in patients, wherein a coagulation inhibitor and normal pooled plasma mixture reduce the factor deficiency effect of patient plasma, and coagulation inhibitor interference in patient plasma, and increases specificity and the sensitivity for detecting lupus anticoagulants in the patient's blood in a phospholipid-dependent clotting assay.